Terms: = Colorectal cancer AND EPAS1, MOP2, 2034, ENSG00000116016, PASD2, HIF2A, Q99814 AND Treatment
12 results:
1. Racial and Ethnic Bias in Risk Prediction Models for colorectal cancer Recurrence When Race and Ethnicity Are Omitted as Predictors.
Khor S; Haupt EC; Hahn EE; Lyons LJL; Shankaran V; Bansal A
JAMA Netw Open; 2023 Jun; 6(6):e2318495. PubMed ID: 37318804
[TBL] [Abstract] [Full Text] [Related]
2. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
3. MicroRNA-related transcription factor regulatory networks in human colorectal cancer.
Hao S; Huo S; Du Z; Yang Q; Ren M; Liu S; Liu T; Zhang G
Medicine (Baltimore); 2019 Apr; 98(15):e15158. PubMed ID: 30985693
[TBL] [Abstract] [Full Text] [Related]
4. Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples.
Sanders H; Qu K; Li H; Ma L; Barlan C; Zhang X; Prentice J; Wolfson D; Crossley B; Sferruzza A; Sninsky J; Ross D; Grupe A; Catanese J; Hantash F; Waldman F
Mol Diagn Ther; 2016 Jun; 20(3):241-53. PubMed ID: 27084556
[TBL] [Abstract] [Full Text] [Related]
5. [Combination of in-situ hepatic split and portal ligation in patients with colorectal cancer and metastatic hepatic spread].
Shchepotin IB; Kolesnik OO; Lukashenko AV; Burlaka AA; Pryĭmak VV; Hanich OV
Klin Khir; 2014 Nov; (11):8-13. PubMed ID: 25675734
[TBL] [Abstract] [Full Text] [Related]
6. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.
de Haas S; Delmar P; Bansal AT; Moisse M; Miles DW; Leighl N; Escudier B; Van Cutsem E; Carmeliet P; Scherer SJ; Pallaud C; Lambrechts D
Angiogenesis; 2014 Oct; 17(4):909-20. PubMed ID: 25012543
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic potential of DNA methylation and transcript levels of HIF1A and epas1 in colorectal cancer.
Rawłuszko-Wieczorek AA; Horbacka K; Krokowicz P; Misztal M; Jagodziński PP
Mol Cancer Res; 2014 Aug; 12(8):1112-27. PubMed ID: 24825851
[TBL] [Abstract] [Full Text] [Related]
8. [Detection and clinical significance of apoptosis related protein in local advanced rectal cancer patients with preoperative neoadjuvant therapy].
Liu Y; Zhang G; Qian J; Zhu YP; Ju HX; Feng HY; Zhu HN; Li DC
Zhonghua Wai Ke Za Zhi; 2012 Oct; 50(10):914-7. PubMed ID: 23302463
[TBL] [Abstract] [Full Text] [Related]
9. Increased cancer incidence in some gallstone diseases, and equivocal effect of cholecystectomy: a long-term analysis of cancer and mortality.
Schmidt M; Småstuen MC; Søndenaa K
Scand J Gastroenterol; 2012 Dec; 47(12):1467-74. PubMed ID: 22946484
[TBL] [Abstract] [Full Text] [Related]
10. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Rittweger K; Gilberg F; Saltz L
Br J Cancer; 2011 Jun; 105(1):58-64. PubMed ID: 21673685
[TBL] [Abstract] [Full Text] [Related]
11. The determinants of traditional Chinese medicine and acupuncture utilization for cancer patients with simultaneous conventional treatment.
Pu CY; Lan VM; Lan CF; Lang HC
Eur J Cancer Care (Engl); 2008 Jul; 17(4):340-9. PubMed ID: 18537814
[TBL] [Abstract] [Full Text] [Related]
12. [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Zhang HG; Li J; Qin SK; Zhang YJ; Song SP; Chu DT
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):228-31. PubMed ID: 17649644
[TBL] [Abstract] [Full Text] [Related]
